Last reviewed · How we verify

NCT03869814

Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types

Status unknown Last updated 5 May 2022
What this trial tests

trial testing Blood Draw in Diagnosis of Cancer of Various Organs in 6,500 participants. Status unknown.

Timeline
5 April 2018
Primary endpoint
13 June 2023
13 September 2023

Quick facts

Lead sponsorClearNote Health
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment6,500
Start date5 April 2018
Primary completion13 June 2023
Estimated completion13 September 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

ClearNote Health — full company profile →

Who can join

Adults 45 to 75, any sex, with Diagnosis of Cancer of Various Organs. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bluestar Genomics is developing a test from whole blood for the early detection of multiple cancers. The goal of this study is to employ genomics, epigenomics and proteomics methodology for the detection of cancer signal in the blood of subjects with solid tumors. The study will include subjects without cancers that will be followed up every 6-months for up to 3-years from blood draw.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
    Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. · · 2023 · cited 72× · PMID 36980276 · DOI 10.3390/cells12060935
  2. Cell-free DNA approaches for cancer early detection and interception.
    Medina JE, Dracopoli NC, Bach PB, Lau A, et al · · 2023 · cited 64× · PMID 37696619 · DOI 10.1136/jitc-2022-006013
  3. Screening for pancreatic cancer has the potential to save lives, but is it practical?
    Mazer BL, Lee JW, Roberts NJ, Chu LC, et al · · 2023 · cited 23× · PMID 37212770 · DOI 10.1080/17474124.2023.2217354
  4. Liquid biopsies for cancer: From bench to clinic.
    Chen Z, Li C, Zhou Y, Yao Y, et al · · 2023 · cited 12× · PMID 37492785 · DOI 10.1002/mco2.329
  5. Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
    Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191
  6. Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.
    Xu Y, Zhu S, Xia C, Yu H, et al · · 2025 · cited 2× · PMID 40670203 · DOI 10.1016/j.scib.2025.06.030
  7. 5-hydroxymethylcytosine analysis reveals stable epigenomic changes in tumor tissue that enable cancer detection in cell-free DNA.
    Xue Y, Ning Y, Friedl V, Haan D, et al · · 2025 · cited 1× · PMID 41261178 · DOI 10.1038/s42003-025-09017-4

Verify or expand the search:

Other trials of Blood Draw

Trials testing the same drug.

Other ClearNote Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03869814.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing